WO2012058826A1 - Medicine for treating psoriasis - Google Patents

Medicine for treating psoriasis Download PDF

Info

Publication number
WO2012058826A1
WO2012058826A1 PCT/CN2010/078478 CN2010078478W WO2012058826A1 WO 2012058826 A1 WO2012058826 A1 WO 2012058826A1 CN 2010078478 W CN2010078478 W CN 2010078478W WO 2012058826 A1 WO2012058826 A1 WO 2012058826A1
Authority
WO
WIPO (PCT)
Prior art keywords
parts
medicine
skin
treating psoriasis
powdered
Prior art date
Application number
PCT/CN2010/078478
Other languages
French (fr)
Chinese (zh)
Inventor
马学荣
Original Assignee
Ma Xuerong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ma Xuerong filed Critical Ma Xuerong
Priority to PCT/CN2010/078478 priority Critical patent/WO2012058826A1/en
Publication of WO2012058826A1 publication Critical patent/WO2012058826A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/19—Acanthaceae (Acanthus family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A61K31/125—Camphor; Nuclear substituted derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/02—Ammonia; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Definitions

  • the invention relates to a medicine which is a medicine for treating psoriasis.
  • a medicine for treating psoriasis which is characterized in that it is made of the following components by weight:
  • An ointment base is also added to the component in an amount of 40 to 60 parts by weight.
  • the invention has good effect in treating psoriasis. According to statistics, there are 207 patients with psoriasis treated by the invention; among them: 124 males and females 83 Person; age: 2 to 20 years old 17 people (including 2 years old 1 person, 6 years old 1 person), 32 to 21 to 30 years old, 73 to 40 years old, 73 people, 41 to 50 years old 43 People, 51 to 57 years old, 25 people, 61 to 70 years old, 15 people, 71 to 82 years old; 2, systemic skin lesions, 129, local skin lesions, 78 people; red skin type, 88 people, vulgaris 112 people, 2 pustules, 5 joints.
  • the invention is convenient to use, and can be applied to the affected area 2 to 3 times a day, and the curative effect is outstanding, safe and reliable, and economical and effective.
  • the amount of each weight component is:
  • the amount of each weight component is:
  • the ointment base is a conventional ointment base such as petrolatum or the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A medicine for treating psoriasis is disclosed. The medicine said above can be made by Rhizoma et Radix Baphicacanthi Cusiae, Realgar, Sulfur, Mirabilitum, Alumen, Camphora, Cortex Pseudolaricis, triamcinolone acetonede acetate and urea.

Description

一种治疗银屑病的药  Medicine for treating psoriasis
技术领域： Technical field:
本发明涉及一种药，是治疗银屑病的药。 The invention relates to a medicine which is a medicine for treating psoriasis.
背景技术： Background technique:
目前对银屑病的病因不太清楚，因而我国药物市场上对治疗银屑病的药物种类并不多，现有的药品大多是激素类药品、中成药之类药品，以及内服中药汤剂及理疗等治疗方法，还有一些抗肿病药物（因毒副作用大，现极少医生应用），但是以上这些药品用在病人身上，绝大多数不起多大作用，因此，对该病的治疗，只有各医疗战线上的医务工作者，发挥各尽所能、各技之长的医治方法，来治疗这种顽固难愈的皮肤病，但是，总的来说，远远达不到理想的治疗效果。 At present, the cause of psoriasis is not clear. Therefore, there are not many types of drugs for treating psoriasis in the Chinese pharmaceutical market. Most of the existing drugs are drugs such as hormonal drugs, proprietary Chinese medicines, and oral Chinese medicine decoctions. Physiotherapy and other treatments, as well as some anti-swelling drugs (due to the toxic side effects, very few doctors apply), but these drugs are used in patients, the vast majority do not have much effect, therefore, the treatment of the disease, Only the medical workers on the medical fronts can use all the best ways and treatments to treat this stubborn and difficult skin disease. However, in general, it is far from the ideal treatment. effect.
发明内容： Summary of the invention:
本发明的目的在于提供一种治疗银屑病效果好的治疗银屑病的药。 It is an object of the present invention to provide a medicament for treating psoriasis which is effective in treating psoriasis.
本发明的技术解决方案是： The technical solution of the present invention is:
一种治疗银屑病的药，其特征是：由下列重量份的组份制成： A medicine for treating psoriasis, which is characterized in that it is made of the following components by weight:
青黛 7 ～ 12 份, 雄黄 3 ～ 6 份, 7 to 12 parts of green barley, 3 to 6 parts of realgar,
硫黄 3 ～ 6 份, 皮硝 3~6 份, 3 to 6 parts of sulfur, 3 to 6 parts of skin nitrate,
明矾 3~6 份, 樟脑 3 ～ 6 份, 3~6 copies of alum, 3-6 parts of camphor,
土槿皮 7 ～ 12 份, 醋酸曲安奈德 0.05 ～ 0.1 份, 7 to 12 parts of earthworms, 0.05 to 0.1 parts of triamcinolone acetonide,
尿素 7 ～ 12 份。 Urea 7 to 12 parts.
组分中还加有软膏基质 40~60 重量份。 An ointment base is also added to the component in an amount of 40 to 60 parts by weight.
本发明治疗银屑病效果好，据统计，经本发明治疗的银屑病人 207 人；其中：男 124 人，女 83 人；年龄： 2~20 岁 17 人（包括 2 岁 1 人， 6 岁 1 人）， 21~30 岁 32 人， 31~40 岁 73 人， 41~50 岁 43 人， 51~60 岁 25 人， 61~70 岁 15 人， 71~82 岁 2 人；全身性皮损 129 人，局部性皮损 78 人；红皮型 88 人，寻常型 112 人，脓疱型 2 人，关节型 5 人。全愈 189 人，显效和有效 18 人，治愈率 91.3% ，有效率 100% （疗效标准：全愈：皮损全部消失、不复发，皮肤恢复正常或留有暂时性色素斑；显效：皮损消失 70% 以上；有效：皮损消失 40% 以上；显效和有效合计为有效率）。 The invention has good effect in treating psoriasis. According to statistics, there are 207 patients with psoriasis treated by the invention; among them: 124 males and females 83 Person; age: 2 to 20 years old 17 people (including 2 years old 1 person, 6 years old 1 person), 32 to 21 to 30 years old, 73 to 40 years old, 73 people, 41 to 50 years old 43 People, 51 to 57 years old, 25 people, 61 to 70 years old, 15 people, 71 to 82 years old; 2, systemic skin lesions, 129, local skin lesions, 78 people; red skin type, 88 people, vulgaris 112 people, 2 pustules, 5 joints. A total of 189 people, markedly effective and effective 18 people, the cure rate is 91.3%, the efficiency is 100% (Efficacy criteria: total healing: all skin lesions disappeared, no recurrence, skin returned to normal or temporary pigmentation spots remained; markedly effective: skin lesions disappeared more than 70%; effective: skin lesions disappeared 40% Above; effective and effective total is efficient).
典型病例： Typical cases:
1 、患者潘某某，女， 49 岁，江苏南通市人，门诊经检查，全头部皮损银屑，全身密集大小皮损，大部分成淤状，红皮型，特别是背、腰、臀部皮肤呈灰黑色增厚变硬无弹性。患病 20 多年，经多家医院治疗无效。后使用本发明药 6 个月后，恢复长出新皮肤，至今三年多没有复发。 1, patient Pan Moumou, female, 49 Aged, Nantong City, Jiangsu Province, outpatient examination, full head lesions, silver, crusted large body lesions, most of the formation of silty, red skin type, especially the back, waist, buttocks skin grayish black thickening and hardening Inelastic. Ill 20 For many years, treatment in several hospitals has been ineffective. After 6 months of using the drug of the present invention, new skin was recovered and there was no recurrence for more than three years.
2 、患者张某某，江苏省南通市人，自 1981 年 10 月发病，四肢皮肤上有不同程度的牛皮癣，瘙痒难忍，痛苦不堪。经多年多家医院治疗无效。后使用本发明药物 1 个月后，痊愈，至今 7 年多没有复发。 2, patient Zhang Moumou, Nantong City, Jiangsu Province, since 1981 10 Onset of the month, there are different degrees of psoriasis on the skin of the limbs, itching is unbearable, and the pain is unbearable. After many years of hospital treatment is invalid. After 1 month of use of the drug of the present invention, it recovered and has not relapsed for more than 7 years.
本发明使用方便， 1 日 2 ～ 3 次涂于患处即可，疗效突出，安全可靠，经济实效。 The invention is convenient to use, and can be applied to the affected area 2 to 3 times a day, and the curative effect is outstanding, safe and reliable, and economical and effective.
下面结合实施例对本发明作进一步说明。 The invention is further illustrated by the following examples.
具体实施方式： detailed description:
实施例 1 ： Example 1
将下列重量份的各组份充分混合制成产品： The following parts by weight are thoroughly mixed to make a product:
青黛（粉末状） 10 份、雄黄（粉末状） 5 份、硫黄（粉末状） 5 份、皮硝（粉末状） 5 份、明矾（粉末状） 5 份、樟脑（粉末状） 5 份、土槿皮（粉末状） 10 份、醋酸曲安奈德 0.1 份、尿素 10 份。 1 日 2 ～ 3 次涂于患处即可。 Barley (powdered) 10 parts, realgar (powdered) 5 parts, sulfur (powdered) 5 parts, skin nitrate (powdered) 5 5 parts of alum, alum (powdered), 5 parts of camphor (powder), 10 parts of earthworm skin (powder), 0.1 part of triamcinolone acetonide, and 10 parts of urea. 1st 2 to 3 Apply to the affected area twice.
实施例 2 ： Example 2:
各重量组分用量为： The amount of each weight component is:
青黛（粉末状） 7 份、雄黄（粉末状） 6 份、硫黄（粉末状） 3 份、皮硝（粉末状） 6 份、明矾（粉末状） 4 份、樟脑（粉末状） 6 份、土槿皮（粉末状） 8 份、醋酸曲安奈德 0.05 份、尿素 12 份。 1 日 2 ～ 3 次涂于患处即可。其余同实施例 1 。 Barley (powdered) 7 parts, realgar (powdered) 6 parts, sulfur (powdered) 3 parts, skin nitrate (powdered) 6 4 parts of alum, alum (powdered), 6 parts of camphor (powder), 8 parts of earthworm skin (powder), 0.05 parts of triamcinolone acetonide, and 12 parts of urea. 1st 2 to 3 Apply to the affected area twice. The rest are the same as in the embodiment 1.
实施例 3 ： Example 3:
各重量组分用量为： The amount of each weight component is:
青黛（粉末状） 12 份、雄黄（粉末状） 3 份、硫黄（粉末状） 6 份、皮硝（粉末状） 3 份、明矾（粉末状） 6 份、樟脑（粉末状） 3 份、土槿皮（粉末状） 12 份、醋酸曲安奈德 0.08 份、尿素 8 份。 1 日 2 ～ 3 次涂于患处即可。其余同实施例 1 。 Barley (powdered) 12 parts, realgar (powdered) 3 parts, sulfur (powdered) 6 parts, skin nitrate (powdered) 3 6 parts of alum, alum (powdered), 3 parts of camphor (powder), 12 parts of earthworm skin (powder), 0.08 parts of triamcinolone acetonide, and 8 parts of urea. 1st 2 to 3 Apply to the affected area twice. The rest are the same as in the embodiment 1.
实施例 4 ： Example 4:
将实施例 1~3 的产品中加入 40~60 份（例 40 份、 50 份、 60 份）软膏基质，再使用。所述软膏基质为常规软膏基质，如凡士林等。 Add 40 to 60 parts of the products of Examples 1 to 3 (40, 50, 60) A portion of the ointment base and reuse. The ointment base is a conventional ointment base such as petrolatum or the like.

Claims (2)

1. 一种治疗银屑病的药，其特征是：由下列重量份的组份制成：A medicine for treating psoriasis, which is characterized in that it is made of the following components by weight:
青黛 7 ～ 12 份, 雄黄 3 ～ 6 份,7 to 12 parts of green barley, 3 to 6 parts of realgar,
硫黄 3 ～ 6 份, 皮硝 3~6 份,3 to 6 parts of sulfur, 3 to 6 parts of skin nitrate,
明矾 3~6 份 ,樟脑 3 ～ 6 份,3~6 copies of alum, 3-6 parts of camphor,
土槿皮 7 ～ 12 份, 醋酸曲安奈德 0.05 ～ 0.1 份,7 to 12 parts of earthworms, 0.05 to 0.1 parts of triamcinolone acetonide,
尿素 7 ～ 12 份。Urea 7 to 12 parts.
2. 根据权利要求 1 所述的一种治疗银屑病的药，其特征是：组分中还加有软膏基质 40~60 重量份。 2. The medicament for treating psoriasis according to claim 1, wherein the component further comprises 40 to 60 parts by weight of an ointment base.
PCT/CN2010/078478 2010-11-05 2010-11-05 Medicine for treating psoriasis WO2012058826A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2010/078478 WO2012058826A1 (en) 2010-11-05 2010-11-05 Medicine for treating psoriasis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2010/078478 WO2012058826A1 (en) 2010-11-05 2010-11-05 Medicine for treating psoriasis

Publications (1)

Publication Number Publication Date
WO2012058826A1 true WO2012058826A1 (en) 2012-05-10

Family

ID=46023946

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2010/078478 WO2012058826A1 (en) 2010-11-05 2010-11-05 Medicine for treating psoriasis

Country Status (1)

Country Link
WO (1) WO2012058826A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102688371A (en) * 2012-06-06 2012-09-26 李承平 Tablet for dispelling wind, nourishing blood, clearing heat and removing dampness
CN104116921A (en) * 2014-07-24 2014-10-29 董宝珍 Externally-applied medicated wine for treating neurodermatitis
CN104173872A (en) * 2014-08-29 2014-12-03 钟书明 Traditional Chinese medicine for treating dermatophytosis
KR101732413B1 (en) 2012-12-21 2017-05-04 엠파이어 테크놀로지 디벨롭먼트 엘엘씨 Location-based authentication scheme

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1261106C (en) * 2004-04-27 2006-06-28 赵树昌 Externally applied liquor for treating psoriasis
CN100551394C (en) * 2007-01-19 2009-10-21 马学荣 Treat psoriatic medicine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1261106C (en) * 2004-04-27 2006-06-28 赵树昌 Externally applied liquor for treating psoriasis
CN100551394C (en) * 2007-01-19 2009-10-21 马学荣 Treat psoriatic medicine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LI, SHAORONG: "Treatment Overview of Traditional Chinese Medicine on Psoriasis", CHINESE JOURNAL OF ETHNOMEDICINE AND ETHNOPHARMACY, no. 5, 2005, pages 194 - 196 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102688371A (en) * 2012-06-06 2012-09-26 李承平 Tablet for dispelling wind, nourishing blood, clearing heat and removing dampness
KR101732413B1 (en) 2012-12-21 2017-05-04 엠파이어 테크놀로지 디벨롭먼트 엘엘씨 Location-based authentication scheme
CN104116921A (en) * 2014-07-24 2014-10-29 董宝珍 Externally-applied medicated wine for treating neurodermatitis
CN104173872A (en) * 2014-08-29 2014-12-03 钟书明 Traditional Chinese medicine for treating dermatophytosis

Similar Documents

Publication Publication Date Title
Meltzer et al. Treating acute rhinosinusitis: comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo
WO2012058826A1 (en) Medicine for treating psoriasis
Lineberry et al. Bupropion-induced erythema multiforme
CN102872241A (en) Traditional Chinese medicinal composition for treating inflammatory dermatosis and preparation thereof
Bali et al. Cyclosporine reduces sclerosis in morphea: a retrospective study in 12 patients and a literature review
WO2014106473A1 (en) Use of glycyrrhetinic acid or glycyrrhizic acid in preparing medicaments for preventing or treating radiation injury of soft tissue
CN104688808B (en) A kind of Whelk-eliminating paste and preparation method thereof
Munnangi et al. Comparative study between intralesional MMR and intralesional BCG in treatment of verruca vulgaris
CN102727639B (en) External-use medicine for treating venereal disease
JP2023552390A (en) Treatment of refractory seizures
Cohen et al. Hypersensitivity produced by the topical application of sulfathiazole
Neri Topical steroids and corticophobia
US10821121B2 (en) Formulation including doxycycline hyclate and method for administering the same
WO2016180119A1 (en) Topical preparation and the use thereof in preparing drugs for treating lumbar disc herniation
CN106880670B (en) A kind of medicine for treating scabies
Deepak et al. Nasal septal perforation in a patient with allergic bronchopulmonary aspergillosis and rhinitis on long term corticosteroids
CN108904638A (en) A kind of multiduty external application combination drug and application
Gnansekaran et al. Clobetasol propionate cream 0.025%: a topical therapeutic for dermatological disorders
Giri et al. A study on drug Prescription pattern in Allergic contact dermatitis at Tertiary Care Teaching Hospital in South India
RU2401123C2 (en) Method of treating psoriasis in children
Tauleha et al. Treatment of Patients with Flu Like Syndrome-Case Series
CN110604797A (en) Formula and preparation method of traditional Chinese medicine powder for treating allergic rhinitis and nasosinusitis
Hahn et al. 0.5 Gy chest X-ray as a potential remedy for COVID-19 disease
CN104324095A (en) Traditional Chinese medicine preparation for treating rheumatic bone diseases and a preparation method thereof
CN108578609A (en) A kind of pharmaceutical composition and its preparation method and application for treating eczema

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10859174

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10859174

Country of ref document: EP

Kind code of ref document: A1